Trial Search Results
Early-Onset Sepsis an NICHD/CDC Surveillance Study
This prospective surveillance study will be conducted over a 2 year period to determine current rates of Early-Onset Sepsis (EOS)/ Early-Onset Meningitis (EOM), associated pathogens, antimicrobial resistance, signs and symptoms and infant outcomes.
Stanford is currently not accepting patients for this trial.
NICHD Neonatal Research Network
Collaborator: Centers for Disease Control and Prevention
- Case Surveillance: Live born infants with gestational age of at least 22 weeks and
birth weight >400 g and <72 hours of age who are delivered at NRN hospitals and have
early-onset sepsis and meningitis defined as isolation of a pathogen from blood or CSF
obtained within 72 hours of birth and provision of appropriate antibiotic treatment
for 5 or more days (or <5 days if death occurs while receiving antibiotic therapy).
- Controls: Live born infants with gestational age of at least 22 weeks and birth weight
>400 g who are delivered at NRN hospitals and have not been evaluated for early-onset
sepsis (<72 hours of age) or if evaluated, they have sterile blood and/or CSF cultures
and were not treated with prolonged antibiotics for clinical "culture negative"
sepsis. Controls for infants with Gram-negative infection will be infants without
early-onset infection. Controls for infants born to mothers with clinical
chorioamnionitis will be infants without early-onset infection born to mothers with
clinical chorioamnionitis. Control infants will be born at the same hospital as cases,
with the same gestational age grouping as cases (22 0/7 - 28 6/7 weeks; 29 0/7 - 33
6/7 weeks; 34 0/7 - 36 6/7 weeks; and ≥ 37 weeks).
- Stillbirths and infants who die in the delivery room will be excluded.
- Infants who die within 12 hours of age will be excluded if they have not been
evaluated for possible infection-ie, do not have a blood culture obtained to identify
Ages Eligible for Study
N/A - 72 Hours
Genders Eligible for Study